Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset.
Schizophrenia Research. 2017-04-01; 182: 84-89
DOI: 10.1016/j.schres.2016.10.023
Lire sur PubMed
1. Schizophr Res. 2017 Apr;182:84-89. doi: 10.1016/j.schres.2016.10.023. Epub
2016 Oct 24.
Validation study of the Medication Adherence Rating Scale. Results from the
FACE-SZ national dataset.
Fond G(1), Boyer L(2), Boucekine M(2), Aden LA(2), Schürhoff F(3), Tessier A(4),
Andrianarisoa M(3), Berna F(5), Brunel L(3), Capdevielle D(6), Chereau I(7),
Mallet J(8), Denizot H(7), Dorey JM(9), Dubertret C(8), Dubreucq J(10), Faget
C(11), Gabayet F(10), Rey R(9), Richieri R(11), Passerieux C(12), Schandrin
A(6), Urbach M(12), Vidailhet P(5), Llorca PM(7), Misdrahi D(13); FACE-SZ
(FondaMental Academic Centers of Expertise for Schizophrenia) group.
Author information:
(1)Fondation FondaMental, Créteil, France; Pôle de Psychiatrie et d’addictologie
des Hôpitaux Universitaires H Mondor, INSERM U955, Eq 15 Psychiatrie Génétique
et psychopathologie, DHU Pe-PSY, Université Paris Est-Créteil, Créteil, France;
Clinique Jeanne d’Arc, Hôpital Privé Parisien, F-94160 Saint-Mandé, France.
Electronic address: .
(2)Fondation FondaMental, Créteil, France; Aix-Marseille University, EA 3279 –
Public Health, Chronic Diseases and Quality of Life – Research Unit, France.
(3)Fondation FondaMental, Créteil, France; Pôle de Psychiatrie et d’addictologie
des Hôpitaux Universitaires H Mondor, INSERM U955, Eq 15 Psychiatrie Génétique
et psychopathologie, DHU Pe-PSY, Université Paris Est-Créteil, Créteil, France.
(4)Centre Hospitalier Charles Perrens, Université de Bordeaux, CNRS UMR
5287-INCIA, F-33076 Bordeaux, France.
(5)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(6)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
INSERM 1061, Montpellier, France.
(7)Fondation FondaMental, Créteil, France; CMP B, CHU, EA 7280 Faculté de
Médecine, Université d’Auvergne, BP 69 63003 Clermont-Ferrand Cedex 1, France.
(8)Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry,
Louis Mourier Hospital, Colombes, Inserm U894, Université Paris Diderot,
Sorbonne Paris Cité, Faculté de médecine, France.
(9)Fondation FondaMental, Créteil, France; Université Claude Bernard Lyon
1/Centre Hospitalier Le Vinatier Pole Est BP 300 39, 95 bd Pinel, 69678 BRON
Cedex, France.
(10)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale, CH Alpes Isère, Grenoble, France.
(11)Fondation FondaMental, Créteil, France; Assistance Publique des Hôpitaux de
Marseille (AP-HM), pôle universitaire de psychiatrie, Marseille, France.
(12)Fondation FondaMental, Créteil, France; Service de psychiatrie d’adulte,
Centre Hospitalier de Versailles, UFR des Sciences de la Santé Simone Veil,
Université Versailles Saint-Quentin en Yvelines, Versailles, France.
(13)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, CNRS UMR 5287-INCIA, F-33076 Bordeaux, France.
OBJECTIVE: The Medication Adherence Rating Scale (MARS) is one of the most
widely used measurements of adherence in schizophrenia (SZ). However, the data
available regarding its psychometric properties are scarce. The aim of this
study was to provide new data regarding the psychometric properties of the MARS
in a multicenter community-dwelling sample of SZ patients.
METHODS: This study was conducted in the French National network of the 10
FondaMental Expert Centers for SZ. The MARS was tested for construct validity,
reliability, external validity and acceptability. In addition, data pertaining
to sociodemographic information, clinical characteristics using the Positive and
Negative Syndrome Scale (PANSS), the Scale to Assess Unawareness in Mental
Disorder (SUMD), the Calgary Depression Scale for Schizophrenia (CDRS) and
therapeutic adherence using the Brief Adherence Rating Scale (BARS) were
collected.
RESULTS: Three hundred and nineteen patients were included. The 3-factor
structure of the MARS was confirmed using confirmatory factor analysis:
RMSEA=0.05, CFI=0.95, and WRMR=0.88. The unidimensionality of each factor was
supported by the satisfactory INFIT statistics. Item internal consistencies were
all higher than 0.15 and the Kuder-Richardson were close to 0.6, except for
factor 2, which was close to 0.5. Significant associations with BARS, PANSS,
CDRS showed satisfactory external validity. The acceptability was excellent as
all patients complete the MARS, without missing values.
CONCLUSION: The MARS is a short self-administered instrument with acceptable
psychometric properties that yields important information about adherence to
pharmacological treatment. Some improvements might be considered to enhance its
validity and reliability.
Copyright © 2016 Elsevier B.V. All rights reserved.
DOI: 10.1016/j.schres.2016.10.023
PMID: 27789187 [Indexed for MEDLINE]